DeepRx develops artificial intelligence tools to help match cancer patients with treatments suited to their individual tumor biology. Its clinical decision-support platform predicts responses to chemotherapy, targeted drugs and immunotherapies. The lead product, COLOXIS, focuses on helping clinicians select treatment for colorectal cancer by estimating the benefit of oxaliplatin. [1] [2]
Co-founded in 2019 by University of Pittsburgh researchers Xinghua Lu, Gregory F. Cooper and Lujia Chen, DeepRx brings biomedical informatics into precision oncology. Its work on COLOXIS has been published in the Journal of Clinical Oncology, and an angel seed investment from practicing oncologists supports further validation of the technology. [1] [3]